28.52
price up icon6.98%   1.86
pre-market  プレマーケット:  28.99   0.47   +1.65%
loading
前日終値:
$26.66
開ける:
$26.26
24時間の取引高:
1.33M
Relative Volume:
0.90
時価総額:
$3.23B
収益:
$10.12M
当期純損益:
$-280.49M
株価収益率:
-9.8685
EPS:
-2.89
ネットキャッシュフロー:
$-188.51M
1週間 パフォーマンス:
+5.98%
1か月 パフォーマンス:
-7.52%
6か月 パフォーマンス:
-38.94%
1年 パフォーマンス:
+25.47%
1日の値動き範囲:
Value
$26.01
$29.36
1週間の範囲:
Value
$25.28
$29.36
52週間の値動き範囲:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
名前
Avidity Biosciences Inc
Name
セクター
Healthcare (1155)
Name
電話
858-401-7900
Name
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
391
Name
Twitter
Name
次回の収益日
2024-12-07
Name
最新のSEC提出書
Name
RNA's Discussions on Twitter

RNA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
28.52 3.23B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 開始されました Citigroup Buy
2025-03-12 開始されました BMO Capital Markets Outperform
2025-03-07 開始されました Scotiabank Sector Outperform
2024-12-20 開始されました H.C. Wainwright Buy
2024-11-26 開始されました RBC Capital Mkts Outperform
2024-09-24 開始されました Goldman Buy
2024-08-28 開始されました Barclays Overweight
2024-05-03 開始されました BofA Securities Buy
2024-03-14 開始されました Cantor Fitzgerald Overweight
2023-05-22 アップグレード Evercore ISI In-line → Outperform
2023-03-31 ダウングレード Evercore ISI Outperform → In-line
2022-07-20 開始されました Chardan Capital Markets Buy
2022-07-12 開始されました Raymond James Strong Buy
2021-09-07 開始されました Evercore ISI Outperform
2021-06-17 開始されました Needham Buy
2021-04-26 再開されました Credit Suisse Outperform
2020-07-07 開始されました Cowen Outperform
2020-07-07 開始されました Credit Suisse Outperform
2020-07-07 開始されました SVB Leerink Outperform
2020-07-07 開始されました Wells Fargo Overweight
すべてを表示

Avidity Biosciences Inc (RNA) 最新ニュース

pulisher
Apr 21, 2025

Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan

Apr 21, 2025
pulisher
Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025
pulisher
Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025
pulisher
Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025
pulisher
Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025
pulisher
Apr 02, 2025

When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 02, 2025

Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider

Apr 01, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times

Mar 31, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Mar 29, 2025
pulisher
Mar 26, 2025

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 22, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise

Mar 22, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Mar 21, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 18, 2025

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com

Mar 18, 2025
pulisher
Mar 18, 2025

Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Citi maintains $70 target on Avidity Biosciences stock post-trial - Investing.com

Mar 18, 2025
pulisher
Mar 17, 2025

Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online

Mar 17, 2025

Avidity Biosciences Inc (RNA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):